The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.
Lead Product(s): Human iPSC-derived cardiac tissues
Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Funding March 03, 2020